We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Pulmonem and the Research Institute of the McGill University Health Centre have commenced US-based subject enrolment in the Phase III clinical trial of the drug, PULM-001, for Covid-19.